During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...

Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even ...

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

A Cumberland County woman, who, earlier this year, was given months to live, is now thriving due to a newly-approved, cutting ...

ROCHESTER, Minn. (WXOW) – Researchers at Mayo Clinic are investigating why multiple myeloma is the most common cancer in the Black community. The team has identified a precursor to myeloma called ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, ...

"Back in the 1990s, multiple myeloma was a dreaded disease and patients had dismal outcomes," Vishwanath Sathyanarayanan, MD, DM, of Apollo Cancer Centers in Bangalore, India, said in an interview.

An expert discusses how frontline management of transplant-ineligible multiple myeloma has progressed from melphalan-based regimens to modern anti-CD38–based combinations, now including emerging ...